Tag: BioNTech
Ultragenyx’s UX053 Phase I/II study termination a minor setback for mRNA...
The study was terminated due to reasons unrelated to safety concerns, although the specific rationale has not been disclosed by the biopharmaceutical company
Pfizer & BioNTech’s mRNA Covid-19 vaccine get UK regulator’s nod
First authorization for a COVID-19 vaccine represents a breakthrough scientific achievement to help combat this devastating pandemic............................